You are here

FDA OKs Second Ovarian Cancer Indication for PARP Inhibitor Rubraca

Agent is now approved for the maintenance treatment of recurrent disease regardless of BRCA status

The FDA has approved rucaparib (Rubraca, Clovis Oncology, Inc.) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The agency granted regular approval for rucaparib in this second, broader, and earlier-line indication on a priority-review timeline based on positive data from a phase 3 trial. Biomarker testing is not required for patients to be prescribed rucaparib in this maintenance treatment indication.

In addition to granting rucaparib approval in this second indication, the FDA converted the approval of the initial treatment indication from accelerated to regular approval.

In December 2017, the FDA accepted the rucaparib supplemental new drug application and granted priority review status. The rucaparib maintenance treatment approval is based on positive results from the phase 3 ARIEL3 study, which evaluated rucaparib in the ovarian cancer maintenance treatment setting among three populations: 1) BRCA-mutant (BRCAmut+), 2) homologous recombination deficiency-positive inclusive of BRCAmut+, and 3) all patients treated in ARIEL3. The study enrolled a total of 564 patients.

ARIEL3 successfully achieved both its primary and key secondary endpoints: extending investigator-assessed progression-free survival versus placebo in all patients treated, regardless of BRCA status.

The most common adverse reactions (greater than or equal to 20% of patients; Common Terminology Criteria for Adverse Events [CTCAE] grade 1–4) were nausea, fatigue/asthenia, abdominal pain/distention, rash, dysgeusia, anemia, aspartate transaminase (AST) and alanine transaminase (ALT) elevation, constipation, vomiting, diarrhea, thrombocytopenia, nasopharyngitis/upper respiratory tract infection, stomatitis, decreased appetite, and neutropenia. The most common laboratory abnormalities (greater than or equal to 25% of patients; CTCAE grade 1–4) were increase in creatinine, decrease in hemoglobin, increase in cholesterol, increase in ALT, increase in increase in AST, decrease in platelets, decrease in leukocytes, decrease in neutrophils, increase in alkaline phosphatase, and decrease in lymphocytes. The majority of adverse reactions and laboratory abnormalities were grade 1–2.

Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase 1 (PARP1), PARP2, and PARP3 being developed in ovarian cancer as well as several additional solid tumor indications. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung, and bladder cancers.

Rucaparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also approved for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for rucaparib.

Source: Clovis Oncology; April 6, 2018.

More Headlines

COMPASS Trial Shows 24% Reduction in Major CV Events
Only 18.7% of Patients Treated Had Uveitis Recurrence
Protein Organizes and Stores DNA for B Cells in Methodical Fashion
Patients’ Bodies Most Common Source of Hospital-Acquired Bloodstream Infections
Growing opioid crisis fueling suicide increase according to study
Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
In Future, Providers May Screen for APOE4 Before Treatment 
MIT Professor Working to Produce Thousands of Drugs on Demand
Agency Scrutinizes Attempts to Block Generics